Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
Open Access
- 10 July 2007
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 12 (1), 81-93
- https://doi.org/10.1016/j.ccr.2007.06.005
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumorsMolecular Cancer Therapeutics, 2006
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJCI Insight, 2006
- The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase InhibitorsClinical Cancer Research, 2006
- IRS-1: Auditing the effectiveness of mTOR inhibitorsCancer Cell, 2006
- Molecular Context of theEGFRMutations: Evidence for the Activation of mTOR/S6K SignalingClinical Cancer Research, 2006
- Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFRNature Genetics, 2005
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell linesProceedings of the National Academy of Sciences of the United States of America, 2005
- Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genesGenes & Development, 2001